CN114344558A - Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof - Google Patents
Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof Download PDFInfo
- Publication number
- CN114344558A CN114344558A CN202210068535.7A CN202210068535A CN114344558A CN 114344558 A CN114344558 A CN 114344558A CN 202210068535 A CN202210068535 A CN 202210068535A CN 114344558 A CN114344558 A CN 114344558A
- Authority
- CN
- China
- Prior art keywords
- polyvinyl alcohol
- cannabidiol
- hydrogel
- wound dressing
- tannic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 94
- 239000004372 Polyvinyl alcohol Substances 0.000 title claims abstract description 59
- 229920002451 polyvinyl alcohol Polymers 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 25
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 25
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 25
- 229940033123 tannic acid Drugs 0.000 claims abstract description 25
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 25
- 229920002258 tannic acid Polymers 0.000 claims abstract description 25
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 23
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 23
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 23
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 23
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 23
- 239000002243 precursor Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 229960003128 mupirocin Drugs 0.000 claims abstract description 19
- 229930187697 mupirocin Natural products 0.000 claims abstract description 19
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 8
- 230000008014 freezing Effects 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 abstract description 36
- 208000027418 Wounds and injury Diseases 0.000 abstract description 36
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 206010048038 Wound infection Diseases 0.000 abstract description 5
- 230000029663 wound healing Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000010257 thawing Methods 0.000 abstract 1
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
A cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and its preparation method are provided. The method comprises the preparation of a hydrogel precursor, the preparation of a drug-loaded hydrogel precursor and the preparation of a drug-loaded hydrogel. The cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing provided by the invention takes cannabidiol and mupirocin as main active ingredients in the wound dressing, and the hydrogel is prepared from tannic acid and polyvinyl alcohol through a freeze-thawing method. The wound dressing prepared from cannabidiol-tannin-polyvinyl alcohol hydrogel by the method has antibacterial and anti-inflammatory properties, and can protect affected parts, prevent wound infection and promote wound healing.
Description
Technical Field
The invention belongs to the technical field of biomedical materials, particularly relates to a medical article and a preparation method thereof, and particularly relates to a cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing and a preparation method thereof.
Background
At present, the conventional wound dressing, such as a band-aid, is limited by its material, and has considerable defects, such as poor air permeability and water resistance, secretion and sweat at the wound can not be discharged in time, and the wound can be soaked in the liquid to cause infection and other conditions, thereby affecting the healing of the wound. When a large area or a special wound with a complex shape is encountered, the traditional band-aid cannot be perfectly attached to the surface of the wound, and the use is not convenient enough. Furthermore, the adhesive coating is very adhesive and may cause pain or even damage to the surrounding skin when the band aid is torn off. In addition, the slow release performance of the wound dressing medicine at the present stage is not enough, and the functions of diminishing inflammation, inhibiting bacteria and the like are also needed to be further improved.
The novel hydrogel wound dressing can effectively solve the problems, and compared with the traditional preparation, the hydrogel has the advantages of good slow release effect, strong skin affinity, large drug-loading rate, good permeability, small toxic and side effects, convenience in use and the like. Therefore, the drug-loaded hydrogel wound dressing can improve the drug slow-release performance, enhance the anti-inflammation, antibacterial and other effects of the wound dressing, and further promote the wound healing.
Disclosure of Invention
The invention aims to solve the defects of the traditional wound dressing, provides a cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and a preparation method thereof, and provides a new solution for postoperative wound, penetrating wound and daily wound treatment.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing is prepared from 6 g-8 g of tannic acid solution, 2 g-4 g of polyvinyl alcohol, 0.1 g-0.4 g of cannabidiol and 0.1 g-0.4 g of mupirocin, the hydrogel is prepared from the tannic acid solution and the polyvinyl alcohol, and the cannabidiol and the mupirocin are used as main drug effect components in the wound dressing.
Further, the concentration of the tannic acid solution is 30% -50%, preferably 50%.
Further, the hydrogel wound dressing is prepared from 7g of tannic acid solution, 3g of polyvinyl alcohol, 0.1-0.4 g of cannabidiol and 0.1-0.4 g of mupirocin. In the preparation of the hydrogel precursor, when the addition amount of the polyvinyl alcohol is selected to be 3g, the state of the hydrogel precursor is optimal, and the finally prepared hydrogel has good rheological property, and the elastic modulus is greater than the viscous modulus, so that the hydrogel is in a good viscoelastic state.
Further, the hydrogel wound dressing is prepared from 6g to 8g of tannic acid solution, 2g to 4g of polyvinyl alcohol, 0.3g of cannabidiol and 0.2g of mupirocin.
Further, the hydrogel wound dressing was prepared from 7g of tannic acid solution, 3g of polyvinyl alcohol, 0.3g of cannabidiol and 0.2g of mupirocin.
A preparation method of the cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing comprises the following steps:
the method comprises the following steps: preparation of hydrogel precursor: mixing the tannic acid solution and the polyvinyl alcohol powder, and stirring the mixture of the tannic acid solution and the polyvinyl alcohol powder in a water bath kettle at 80 ℃ until the tannic acid solution and the polyvinyl alcohol powder are uniformly mixed to obtain uniform viscous liquid;
step two: preparation of drug-loaded hydrogel precursor: standing the hydrogel precursor prepared in the step one for 2min, cooling to 40 ℃, adding cannabidiol and mupirocin powder, and uniformly stirring; in the preparation of the drug-loaded hydrogel precursor, the temperature is cooled to 40 ℃ in order to prevent the effect of cannabidiol and mupirocin due to excessive temperature.
Step three: preparing a drug-loaded hydrogel: and (3) pouring the drug-loaded hydrogel precursor obtained in the step two into a mould, putting the mould into a refrigerator with the temperature of-20 ℃ for freezing for 4h-8h, taking out the mould after freezing, and unfreezing the mould at room temperature to obtain the cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing.
Further, in step three, the freezing time is 6 h.
Compared with the prior art, the invention has the beneficial effects that:
1. after the cannabidiol and the mupirocin are loaded in the hydrogel, the drug effect of the wound dressing is improved, and the wound dressing has stronger antibacterial, anti-inflammatory and antioxidant effects and stronger bacteriostatic effect on gram-positive bacteria.
2. The product can be applied to wound to stop bleeding and relieve pain, and has antibacterial effect and can prevent wound inflammation.
3. Most of the medicinal components selected in the invention are selected from natural plant extracts, and are non-toxic and non-irritant.
4. The product has soft texture, is not easy to drop, has antibacterial effect, can prevent wound infection and inflammation, has drug slow release function, and can achieve sustained release of medicinal components, thereby having effects of protecting wound, preventing infection, and promoting wound healing.
Drawings
FIG. 1 is a diagram of a finished hydrogel product;
FIG. 2 is a microscopic view of the hydrogel taken by a scanning electron microscope (magnification factor 16.53K);
FIG. 3 is a graph of the DPPH radical scavenging rate of the cannabidiol-tannin-polyvinyl alcohol hydrogel release fluid of example 1 as a function of time;
FIG. 4 is a plot of the zone of inhibition of cannabidiol-tannin-polyvinyl alcohol hydrogel against Staphylococcus aureus;
FIG. 5 is a control group of bacteriostatic rate test of cannabidiol-tannin-polyvinyl alcohol hydrogel against Staphylococcus aureus;
FIG. 6 is a test set of the bacteriostatic rate of cannabidiol-tannin-polyvinyl alcohol hydrogel against Staphylococcus aureus;
FIG. 7 is a graph of the DPPH radical scavenging rate of cannabidiol-tannin-polyvinyl alcohol hydrogel release fluid over time in example 2
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention takes tannic acid and polyvinyl alcohol as main components of hydrogel, and cannabidiol and mupirocin as main effective components. The cannabidiol-tannin-polyvinyl alcohol hydrogel is simple and convenient in preparation method, high in safety, green and environment-friendly, good in biocompatibility and capable of preventing wound infection and promoting wound healing, and toxic chemical reagents are not involved in the preparation process.
Compared with other hydrogels, the hydrogel provided by the invention has good oxidation resistance, has a very obvious antibacterial effect on gram-positive bacteria, and prevents wound infection. At present, no research on the wound dressing of the cannabidiol hydrogel is carried out, and the hydrogel plays a role in slow release for the release of the cannabidiol, so that the drug effect time can be prolonged.
The cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing can embody the advantages of the hydrogel wound dressing. The structure of the tannic acid and the polyvinyl alcohol enables the tannic acid and the polyvinyl alcohol to be crosslinked to form hydrogel through abundant hydrogen bond acting force, the dressing strengthens the hydrogen bond acting force between the tannic acid and the polyvinyl alcohol through a freeze-thaw method, and no additional chemical crosslinking agent needs to be introduced, so that the biological safety is improved. Mupirocin is an antibiotic anti-infective drug, and can be added into hydrogel to improve antibacterial property of hydrogel and enhance wound infection preventing effect. Cannabidiol is a cannabis extract, has no psychoactive properties, and has anti-tumor, drug addiction intervention, anti-inflammatory, antioxidant, and skin repair promoting effects. At present, no research for preparing a hydrogel wound dressing loaded with cannabidiol exists, but the cannabidiol is loaded into the tannin-polyvinyl alcohol hydrogel creatively by a direct mixing method, the antioxidation effect of the cannabidiol and the bacteriostatic effect of mupirocin are jointly effective, and the antioxidation effect of the tannic acid in the hydrogel matrix is added, so that the effect of the hydrogel on promoting wound healing can be obviously improved.
Example 1:
(1) preparation of hydrogel precursor: mixing 7g of 50% tannic acid solution and 3g of polyvinyl alcohol powder to make the mass fraction of polyvinyl alcohol in the total mass of the hydrogel dressing 30%, and stirring the mixture in a water bath kettle at 80 deg.C for 1h until a uniform viscous liquid is obtained.
(2) Preparation of drug-loaded hydrogel precursor: and (2) standing the hydrogel precursor prepared in the step (1), cooling to 40 ℃, adding 0.3g of cannabidiol and 0.2g of mupirocin powder, and then uniformly stirring.
(3) Preparing a drug-loaded hydrogel: pouring the drug-loaded hydrogel precursor obtained in the step (2) into a mold, putting the mold into a refrigerator with the temperature of-20 ℃ for freezing for 6h, taking out the mold after 6h, and unfreezing to obtain the cannabidiol-tannin-polyvinyl alcohol hydrogel.
Under the conditions of example 1, the cannabidiol-tannin-polyvinyl alcohol hydrogel has strong oxidation resistance (DPPH radical scavenging rate is used to indicate the oxidation resistance), fig. 3 shows the DPPH scavenging rate of the cannabidiol-tannin-polyvinyl alcohol hydrogel in a release solution with the pH of 7.4, and the DPPH scavenging rate of the release solution after 160min can reach 65.5% ± 2.7%.
Under the conditions of example 1, the cannabidiol-tannin-polyvinyl alcohol hydrogel has a very strong bacteriostatic effect on gram-positive bacteria, and the experimental result takes the bacteriostatic effect of the hydrogel on staphylococcus aureus as an example: as shown in fig. 4, 5 and 6, the hydrogel is against staphylococcus aureus (CFU 10)6) The diameter of the bacteriostatic circle is 14.33 +/-0.47 mm; bacteriostasis rate (CFU 10 ═ 10)3) Reaching 100 percent.
Example 2:
(1) preparation of hydrogel precursor: mixing 7g of 50% tannic acid solution and 3g of polyvinyl alcohol powder to make the mass fraction of polyvinyl alcohol in the total mass of the hydrogel dressing 30%, and stirring the mixture in a water bath kettle at 80 deg.C for 1h until a uniform viscous liquid is obtained.
(2) Preparation of drug-loaded hydrogel precursor: and (2) standing the hydrogel precursor prepared in the step (1), cooling to 40 ℃, adding 0.1g of cannabidiol and 0.2g of mupirocin powder, and then uniformly stirring.
(3) Preparing a drug-loaded hydrogel: pouring the drug-loaded hydrogel precursor obtained in the step (2) into a mold, putting the mold into a refrigerator with the temperature of-20 ℃ for freezing for 6h, taking out the mold after 6h, and unfreezing to obtain the cannabidiol-tannin-polyvinyl alcohol hydrogel.
Under the conditions of example 2, the cannabidiol-tannin-polyvinyl alcohol hydrogel has stronger oxidation resistance (DPPH free radical scavenging rate is used for representing the oxidation resistance), but is slightly lower than the oxidation resistance of example 1, as shown in FIG. 7, the DPPH scavenging rate of the cannabidiol-tannin-polyvinyl alcohol hydrogel in the release solution with the pH of 7.4 in example 2 can reach 47.2% + -0.2% after 160 min.
Under the conditions of example 2, the cannabidiol-tannin-polyvinyl alcohol hydrogel still has a very strong bacteriostatic effect on gram-positive bacteria, and the bacteriostatic effect is the same as the result in example 1: hydrogel dressing for staphylococcus aureus (CFU 10)6) The diameter of the bacteriostatic circle is 14.33 +/-0.47 mm; bacteriostasis rate (CFU 10 ═ 10)3) Reaching 100 percent.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (7)
1. A cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing is characterized in that: the hydrogel wound dressing is prepared from 6g to 8g of tannic acid solution, 2g to 4g of polyvinyl alcohol, 0.1g to 0.4g of cannabidiol and 0.1g to 0.4g of mupirocin.
2. A cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing as claimed in claim 1, wherein: the concentration of the tannic acid solution is 30-50%.
3. A cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing as claimed in claim 1, wherein: the hydrogel wound dressing is prepared from 7g of tannic acid solution, 3g of polyvinyl alcohol, 0.1-0.4 g of cannabidiol and 0.1-0.4 g of mupirocin.
4. A cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing as claimed in claim 1, wherein: the hydrogel wound dressing is prepared from 6g to 8g of tannic acid solution, 2g to 4g of polyvinyl alcohol, 0.3g of cannabidiol and 0.2g of mupirocin.
5. A cannabidiol-tannic acid-polyvinyl alcohol hydrogel wound dressing as claimed in claim 1, wherein: the hydrogel wound dressing is prepared from 7g of a tannic acid solution, 3g of polyvinyl alcohol, 0.3g of cannabidiol and 0.2g of mupirocin.
6. A method of preparing a cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing as claimed in any one of claims 1 to 5, wherein: the method comprises the following steps:
the method comprises the following steps: preparation of hydrogel precursor: mixing the tannic acid solution and the polyvinyl alcohol powder, and stirring the mixture of the tannic acid solution and the polyvinyl alcohol powder in a water bath kettle at 80 ℃ until the tannic acid solution and the polyvinyl alcohol powder are uniformly mixed to obtain uniform viscous liquid;
step two: preparation of drug-loaded hydrogel precursor: standing the hydrogel precursor prepared in the step one for 2min, cooling to 40 ℃, adding cannabidiol and mupirocin powder, and uniformly stirring;
step three: preparing a drug-loaded hydrogel: and (3) pouring the drug-loaded hydrogel precursor obtained in the step two into a mould, putting the mould into a refrigerator with the temperature of-20 ℃ for freezing for 4h-8h, taking out the mould after freezing, and unfreezing the mould at room temperature to obtain the cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing.
7. The method of preparing a cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing as claimed in claim 6, wherein: in the third step, the freezing time is 6 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210068535.7A CN114344558A (en) | 2022-01-20 | 2022-01-20 | Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210068535.7A CN114344558A (en) | 2022-01-20 | 2022-01-20 | Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114344558A true CN114344558A (en) | 2022-04-15 |
Family
ID=81090548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210068535.7A Pending CN114344558A (en) | 2022-01-20 | 2022-01-20 | Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114344558A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115124752A (en) * | 2022-08-11 | 2022-09-30 | 东莞理工学院 | Composite hydrogel dressing and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005112735A (en) * | 2003-10-03 | 2005-04-28 | Hakuto Co Ltd | Gel composition having stretchability and method for producing the same |
| CN109762182A (en) * | 2019-01-02 | 2019-05-17 | 大连理工大学 | A kind of high intensity-porous structure polyvinyl alcohol-tannin acid hydrogel preparation method and application |
| US20200352849A1 (en) * | 2019-05-07 | 2020-11-12 | Adam M. Rotunda | Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment |
| CN112745515A (en) * | 2021-01-18 | 2021-05-04 | 无锡市第二人民医院 | Silver-loaded tannin polyphenol crosslinked polyvinyl alcohol antibacterial hydrogel and preparation method thereof |
| CN113201152A (en) * | 2021-04-29 | 2021-08-03 | 哈尔滨工业大学 | Preparation method of multi-responsiveness self-healing self-adhesion hydrogel |
| CN113499324A (en) * | 2021-07-05 | 2021-10-15 | 海南艾斯卓普科技有限公司 | Cannabidiol nano analgesic patch with bacterial cellulose-magnetic graphene oxide as base material and preparation method thereof |
-
2022
- 2022-01-20 CN CN202210068535.7A patent/CN114344558A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005112735A (en) * | 2003-10-03 | 2005-04-28 | Hakuto Co Ltd | Gel composition having stretchability and method for producing the same |
| CN109762182A (en) * | 2019-01-02 | 2019-05-17 | 大连理工大学 | A kind of high intensity-porous structure polyvinyl alcohol-tannin acid hydrogel preparation method and application |
| US20200352849A1 (en) * | 2019-05-07 | 2020-11-12 | Adam M. Rotunda | Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment |
| CN112745515A (en) * | 2021-01-18 | 2021-05-04 | 无锡市第二人民医院 | Silver-loaded tannin polyphenol crosslinked polyvinyl alcohol antibacterial hydrogel and preparation method thereof |
| CN113201152A (en) * | 2021-04-29 | 2021-08-03 | 哈尔滨工业大学 | Preparation method of multi-responsiveness self-healing self-adhesion hydrogel |
| CN113499324A (en) * | 2021-07-05 | 2021-10-15 | 海南艾斯卓普科技有限公司 | Cannabidiol nano analgesic patch with bacterial cellulose-magnetic graphene oxide as base material and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| KYUNG HWA HONG: "Polyvinyl alcohol/tannic acid hydrogel prepared by a freeze-thawing process for wound dressing applications", 《POLYMER BULLETIN》 * |
| 熊方武等: "《中国临床药物大辞典 化学药卷 下》", 31 August 2018, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115124752A (en) * | 2022-08-11 | 2022-09-30 | 东莞理工学院 | Composite hydrogel dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN102058900B (en) | Waterproof liquid bandage for wound surface protection and preparation method thereof | |
| CN105778126A (en) | Genipin cross-linked biogel as well as preparation method and application thereof | |
| JP2002524203A (en) | Anti-inflammatory and antibacterial uses of bioactive glass compositions | |
| CN109432481A (en) | A kind of polyurethane dressing of hemostatic and antibacterial and preparation method thereof | |
| CN109248333B (en) | Medical dressing for resisting bacteria and promoting wound healing and preparation method and application thereof | |
| CN102772801B (en) | Wound spray for treating bruises and preparation method of wound spray | |
| CN114949324B (en) | Preparation method of biocompatible antibacterial gel film | |
| CN102380123B (en) | Collagen membrane medical dressing and preparation method thereof | |
| CN101927029A (en) | Preparation method of chitosan/polyvinyl alcohol sponge dressing containing nano-silver | |
| CN115124738B (en) | Double-layer bionic drug-loaded hydrogel and preparation and application thereof | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| CN106110383A (en) | A kind of chitosan alginate dressing and freeze-drying process thereof | |
| CN107617121A (en) | A kind of skin wound biology induced activity dressing and its preparation method and application | |
| CN114344558A (en) | Cannabidiol-tannin-polyvinyl alcohol hydrogel wound dressing and preparation method thereof | |
| CN108815381B (en) | Traditional Chinese medicine silver titanate composite porous material for burn wound healing and preparation method and application thereof | |
| CN104740141B (en) | A kind of antimicrobial spray and preparation method thereof | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| CN108619550A (en) | A kind of hydrogel and preparation method thereof | |
| CN108175850A (en) | A kind of chitosan oligosaccharide gelling agent of wound healing and preparation method thereof | |
| CN111616367A (en) | Preparation method of lily polysaccharide microcapsule | |
| CN108452370B (en) | Composite supermolecule hydrogel and preparation method thereof | |
| CA2283314C (en) | Ointment for the treatment of burns and of other skin diseases | |
| CN108939141B (en) | Traditional Chinese medicine composite porous scaffold material for burn wound healing and preparation method and application thereof | |
| CN101797376A (en) | Preparation method of modified collagen film |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220415 |
|
| RJ01 | Rejection of invention patent application after publication |